• Facebook
  • Twitter
  • Linked In
  • Google+
back top




830 Winter Street, 3rd Floor
Waltham, MA 02451

Tel +1 781 547 7900
Fax +1 781 547-4452

Histogenics was incorporated in 2000 with an initial focus of developing products that meaningfully improve the lives of patients with defects in cartilage and joints. In May 2011, the company acquired ProChon Biotech, Ltd. (ProChon), a privately-owned biotechnology company based in Israel, which enabled a synthesis of products, technology and materials science by establishing a robust scientific and technology platform targeting tissue repair solutions.

Histogenics’ goal is to become a leading regenerative medicine company developing, marketing and commercializing products in the musculoskeletal segment of the marketplace. The company plans to build its core technology platform as well as expand its clinical products’ therapeutic applications to develop new and innovative solutions. Histogenics leverages a combination of the latest advances in molecular biology and proprietary materials sciences to create products designed to help improve patient outcomes.


Joint, or articular, cartilage covers the ends of bones and allows for joints to glide smoothly with minimal friction. Cartilage damage, or chondral defects, can be caused by acute trauma, such as a bad fall or sports-related injury, or by repetitive trauma, such as general wear over time. Unlike other tissues in the body, joint cartilage has no innate ability to repair itself, making any injury permanent. Left untreated, even a small chondral defect can expand in size and progress to debilitating arthritis, ultimately necessitating a joint replacement procedure.

Debridement and microfracture procedures are the most frequently performed surgical procedures for treatment for cartilage damage. Debridement does not repair cartilage damage, as its only goal is to improve symptoms. Microfracture is considered the current standard of care for severe chondral defects due to its simplicity, its short-term success in improving symptoms in many patients, its safety profile and the lack of other viable alternatives. However, microfracture has been unsuccessful in reliably solving the underlying problem of cartilage damage because the repair tissue formed by the procedure is incapable of withstanding the normal shock and shear forces that joint cartilage sustains.

In addition to its inability to solve the underlying problem – damage to the articular cartilage – microfracture is associated with numerous other drawbacks and limitations, including the following:

  • Modest Efficacy
  • Limited Long-Term Patient Benefits
  • Extended Patient Recovery

ACI and osteochondral grafting have drawbacks and limitations similar to those affecting debridement and microfracture, and also are associated with the following:

  • Technically Demanding Surgeries
  • Negative Safety Profile